MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

TG Therapeutics Inc

Closed

SectorHealthcare

40.29 2.1

Overview

Share price change

24h

Current

Min

39.35

Max

41.01

Key metrics

By Trading Economics

Income

19M

23M

Sales

24M

108M

P/E

Sector Avg

246.467

57.333

EPS

0.15

Profit margin

21.566

Employees

338

EBITDA

17M

33M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+8.89% upside

Dividends

By Dow Jones

Next Earnings

30 kwi 2025

Market Stats

By TradingEconomics

Market Cap

912M

5.8B

Previous open

38.19

Previous close

40.29

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

TG Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 sie 2024, 20:01 UTC

Earnings

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Peer Comparison

Price change

TG Therapeutics Inc Forecast

Price Target

By TipRanks

8.89% upside

12 Months Forecast

Average 43 USD  8.89%

High 55 USD

Low 11 USD

Based on 6 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

38.89 / 40.1899Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.